Eledon Pharmaceuticals (NASDAQ:ELDN) reported a full‑year 2025 net loss of $45.6 million and earnings per share of $(0.52). The company did not disclose a Q4 net loss figure, but it reported a non‑GAAP quarterly EPS of $(0.10), beating the consensus estimate of $(0.20). The full‑year 2025 EPS of $(0.52) also surpassed analysts’ expectations of $(0.37), a beat of $0.15 per share.
R&D spending rose to $66.3 million in 2025, up from $52.0 million in 2024, reflecting intensified investment in the kidney transplantation program and the expansion of the tegoprubart manufacturing scale‑up. General and administrative expenses fell to $17.0 million from $18.6 million, largely due to lower stock‑based compensation. Operating cash burn for the nine months ended December 31, 2025 was $48.3 million, unchanged from the same period a year earlier, underscoring the company’s continued cash outflow as it funds clinical development.
Management highlighted the progress of tegoprubart, the company’s lead anti‑CD40L antibody. "Over the past year, Eledon has made significant progress advancing tegoprubart, our anti‑CD40L antibody, as a potential next‑generation immunosuppressive therapy across multiple transplantation settings," said CEO David‑Alexandre C. Gros. "The over 100 patients treated across our transplantation programs to date provide a growing body of evidence that reinforces our conviction that tegoprubart can address key safety and efficacy issues with current standard‑of‑care transplant immunosuppression." Gros added that the company anticipates multiple important milestones this year, including regulatory engagement to support advancement into Phase 3 development in kidney transplantation, initiation of an additional islet transplantation trial in type 1 diabetes, and the start of a clinical trial in liver transplantation.
Eledon ended 2025 with approximately $133.3 million in cash, cash equivalents, and short‑term investments, which the company expects to fund operations for at least 12 months. The company reiterated that additional financing will be required to sustain its clinical program beyond that horizon, highlighting a near‑term capital need. The company’s cash position and ongoing burn rate underscore the importance of future funding rounds to support the planned Phase 3 and other trials.
The market reacted positively to the earnings release, with analysts noting the narrower quarterly loss and encouraging clinical data for tegoprubart. The company’s progress in multiple transplant indications and the FDA orphan drug designation for liver transplantation were cited as key tailwinds, while the continued cash burn and need for future financing were identified as headwinds.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.